lencana Anda Rentang 52M $12–$21 0% of range Peringkat Analis SELL 7 analysts Target Harga $12 +1% upside P/E -176.4 ROE -6.0% Margin Laba Bersih -14.6%

AMRN Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu

03
Harga $12.35
Kapitalisasi Pasar (MRQ) $5.19B
P/E (TTM) -176.4
EPS (TTM) $-0.07
Pendapatan (TTM) $186M
ROE (TTM) -6.0%
Rentang 52M $12–$21

AMRN Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda

04
rentang
batang

Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.

Pemecahan saham 3
Tanggal ex-dividen Pemecahan Tipe
11 April 2025 1-for-20 Terbalik
18 Jan. 2008 1-for-10 Terbalik
19 Okt. 1998 1-for-10 Terbalik

Tentang Amarin Corporation plc - American Depositary Shares Tinjauan perusahaan dari Wikipedia

05 · wikidata

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline's Lovaza.

History

Amarin Corporation plc (formerly Ethical Holdings plc) was originally incorporated in England as a private limited company on March 1, 1989, and later re-registered as a public company on March 19, 1993. In 2002, the company suffered losses worth $37 million; 2003 losses exceeded $19 million. As of 2005, it was developing neurology drugs. It developed Miraxion to treat serious hereditary neurodegenerative disease.

In December 2007, Amarin acquired Ester Neurosciences Limited for US$8.1 million. In 2011, CEO Joe Zakrzewski said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States.

Products and development

Vascepa (USA) / Vazkepa (EU)

Amarin´s sole product VASCEPA® came on the market in 2013 for triglyceride levels >=500 milligrams per deciliter. In December 2019, the FDA approved "...the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher. Patients must also have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease....Vascepa is the first FDA approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy.

Furthermore, VASCEPA® is in use in clinical trials by 3rd parties to see, if it has an effect on Alzheimer, Colon Cancer, Nonalcoholic Steatohepatitis (NASH), and other diseases.

HLS Therapeutics, Amarin´s license partner in Canada, presented results of their COVID-19 clinical trial for Vascepa at National Lipid Association Scientific Sessions 2020, December 12. The results demonstrated a 25% reduction of hs-CRP, a biomarker for inflammation. Most people with COVID-19 die, because of a cytokine storm, which causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines. Two more COVID-19 studies are actually running with Vascepa to validate and proof further benefits.

On January 28, the Committee for Medicinal Products for Human Use gave a positive recommendation for Vazcepa (its name in the EU), which the European Commission finally approved on March 30.

Patent disputes

On March 30, 2020, the designated patent judge in the U.S. District Court for the District of Nevada, Miranda Du, ruled for generic-drug makers Hikma Pharmaceuticals and Dr. Reddy's Laboratories in a lawsuit with Amarin over patents on Amarin's drug, Vascepa. Soon after, on April 2, 2020, Amarin filed an appeal of the ruling. The appeal was lost and an en-banc was also not granted, afterwards. On November 30, three weeks after Hikma Pharmaceuticals started the distribution of their generic version of Vascepa, Amarin filed a complaint of patent infringement against Hikma. On February 11, 2021, Amarin filed a petition for certiorari with the US Supreme Court. On June 21, 2021, the petition was denied.

== Finance ==

Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗

Wikidata ↗

sektorHealthcare industriBiotechnology karyawan80 negaraIE

Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS

06
Pendapatan$214M
2016-12-31 → 2025-12-31
EPS$-0.09
2016-12-31 → 2025-12-31
Arus Kas Bebas·
2016-12-31 → 2020-12-31
Margin bersih-14.6%
2016-12-31 → 2025-12-31
Valuasi & Rasio 07–12

Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?

Metrik Tren 5 Tahun AMRN rata-rata 5T Median Rekan Kesimpulan
P/E (TTM) -176.4rata-rata 5T ≈591.4 ≈591.4 · ·
P/S (TTM) 27.9rata-rata 5T ≈22.7 ≈22.7 · ·
P/B (MRQ) 11.7rata-rata 5T ≈11.3 ≈11.3 · ·
Price / Cash Flow (Harga / Arus Kas) 764.0rata-rata 5T ≈589.2 ≈589.2 · ·
Harga / Nilai Buku Berwujud (MRQ) 12.0rata-rata 5T ≈18.7 ≈18.7 · ·

Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.

nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median

Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya

14
Kejutan Rata-rata 49.9%
Laporan Berikutnya Okt 27, 2026
PeriodeLaporanEPS AktualEPS EstimasiKejutan
30 Juni 2026 Jul 28, 2026 $-0.02 $-0.01 -96.1%
31 Maret 2026 $-0.09 $0.09 -203.8%
31 Des. 2025 $0.01 $0.00 —
30 Sep. 2025 $0.08 $-0.58 113.8%
30 Juni 2025 $0.66 $-0.18 466.3%
31 Maret 2025 $-0.76 $-0.58 -30.7%

Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas

15
Laporan Laba Rugi 18
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue $214M$229M$307M$369M$583M$614M$430M$229M$181M$130M$82M$54M
Cost of Revenue ····$121M$131M$96M$55M$45M$34M$28M$20M
Gross Profit $121M$81M$166M$242M$462M$483M$334M$175M$136M$96M$54M$34M
R&D Expense $20M$21M$22M$30M$29M$39M$34M$56M$47M$50M$51M$50M
SG&A Expense $115M$152M$200M$304M$408M$463M$324M$227M$135M$111M$101M$79M
Operating Expenses $171M$173M$233M$348M$451M$502M$358M$283M$182M$161M$152M$130M
Operating Income $-50M$-92M$-68M$-106M$11M$-20M$-24M$-108M$-46M$-66M$-98M$-96M
Interest Expense $7.0K$7.0K$8.0K$15.0K$129.0K$3M$7M$9M$10M$19M$20M$19M
Interest Income $11M$13M$12M$3M$1M$5M$8M$1M$429.0K$234.0K$132.0K$96.0K
Other Non-op $3M$1M$2M$-740.0K$-302.0K$104.0K$-75.0K$-326.0K$74.0K$-482.0K$-228.0K$4M
Pretax Income $-36M$-77M$-54M$-104M$11M$-17M$-22M$-116M$-55M$-76M$-118M$-59M
Income Tax $3M$5M$5M$2M$4M$745.0K$164.0K$96.0K$13M$10M$-3M$-3M
Net Income $-39M$-82M$-59M$-106M$8M$-18M$-23M$-116M$-68M$-86M$-115M$-56M
EPS (Basic) $-0.09$-0.20$-0.15$-0.26$0.02$-0.05$-0.07$-0.39$-0.25$-0.41$-0.83$-0.32
EPS (Diluted) $-0.09$-0.20$-0.15$-0.26$0.02$-0.05$-0.07$-0.39$-0.25$-0.41$-0.83$-0.36
Shares (Basic) 414,984,000410,937,000407,655,000401,155,000395,992,000381,759,000342,538,000297,237,000270,652,000211,874,000180,654,000173,719,000
Shares (Diluted) 414,984,000410,937,000407,655,000401,155,000402,480,000381,759,000342,538,000297,237,000270,652,000211,874,000180,654,000173,824,000
EBITDA $-50M$-92M$-68M··$-20M·$-108M$-46M$-66M$-98M$-96M
Neraca 27
Metrik Tren 202520242023202220212020201920182017201620152014
Cash & Equivalents $135M$121M$199M$218M$219M$187M$645M$249M$74M$98M$107M$120M
Short-term Investments $168M$173M$121M$92M$235M$314M······
Receivables $127M$122M$134M$131M$164M$155M$116M$67M$45M$20M$14M$8M
Inventory $196M$166M$259M$229M$235M$189M$77M$58M$30M$21M$19M$14M
Prepaid Expense $24M$13M$12M$19M$22M$31M$13M$3M$3M$7M$3M$3M
Other Current Assets ···········$3M
Current Assets $650M$595M$725M$689M$879M$879M$855M$378M$153M$146M$144M$145M
PP&E (Net) $12.0K$16.0K$114.0K$874.0K$1M$2M$2M$63.0K$28.0K$78.0K$243.0K$381.0K
PP&E (Gross) $1M$1M$1M$3M$3M$4M$3M$902.0K$844.0K$821.0K$997.0K$969.0K
Accum. Depreciation $1M$1M$1M$2M$2M$2M$1M$839.0K$816.0K$755.0K$754.0K$588.0K
Intangibles $13M$16M$19M$22M$24M$14M$15M$7M$8M$9M$9M$10M
Other Non-current Assets $1M$1M$1M$458.0K$456.0K$432.0K$1M$174.0K$174.0K$741.0K$174.0K$3M
Total Assets $671M$685M$832M$886M$1.07B$966M$882M$386M$162M$167M$173M$171M
Accounts Payable $45M$40M$53M$65M$115M$106M$50M$38M$25M$6M$11M$9M
Current Liabilities $194M$180M$259M$259M$371M$307M$242M$157M$109M$76M$51M$40M
Capital Leases $6M$8M$9M$10M$9M$9M$9M·····
Other Non-current Liabilities $11M$12M$9M$8M$8M$6M$4M$11M$1M$710.0K$335.0K$386.0K
Total Liabilities $211M$199M$280M$291M$401M$339M$274M$233M$227M$176M$301M$260M
Long-term Debt ······$50M$80M$92M$94M$92M$105M
Total Debt ·····$0·$80M$93M$101M$106M$105M
Common Stock $310M$305M$303M$299M$294M$290M$269M$247M$209M$207M$150M$143M
Paid-in Capital $1.92B$1.91B$1.90B$1.89B$1.86B$1.82B$1.76B$1.28B$978M···
Retained Earnings $-1.71B$-1.67B$-1.59B$-1.53B$-1.42B$-1.43B$-1.41B$-1.39B$-1.27B$-1.20B$-1.12B$-970M
Treasury Stock $67M$65M$64M$62M$61M$51M$36M$10M$4M$1M$411.0K$217.0K
Stockholders' Equity $459M$486M$552M$595M$667M$628M$608M$152M$-65M$-9M$-129M$-88M
Liabilities + Equity $671M$685M$832M$886M$1.07B$966M$882M$386M$162M$167M$173M$171M
Shares Outstanding 416,214,102411,584,851408,824,093408,824,093396,598,008392,538,081360,103,901325,850,013271,022,011269,363,696183,403,263174,590,372
Arus Kas 17
Metrik Tren 202520242023202220212020201920182017201620152014
D&A ·······$23.0K$62.0K$138.0K$166.0K$198.0K
Stock-based Comp $14M$18M$16M$26M$37M$46M$31M$19M$14M$14M$14M$9M
Deferred Tax ········$11M$9M$-4M$-4M
Amort. of Intangibles $3M$3M$3M$3M$2M$1M$679.0K$646.0K$646.0K$645.0K$646.0K$646.0K
Restructuring $36M$0$11M$14M$14M·······
Operating Cash Flow $7M$-31M$7M$-180M$-67M$-22M$-9M$-95M$-33M$-72M$-84M$-75M
CapEx ·····$252.0K$2M$58.0K$12.0K$21.0K$28.0K·
Investing Cash Flow $9M$-46M$-26M$175M$104M$-377M$-2M$-58.0K$-12.0K$-21.0K··
Net Debt Issued ·····$-50M·$-15M$-3M···
Stock Issued ······$440M$265M·$65M··
Stock Repurchased ··········$194.0K·
Net Stock Activity ·······$265M·$65M$-194.0K·
Financing Cash Flow $-2M$-1M$230.0K$-379.0K$-5M$-59M$410M$271M$8M$63M··
Net Change in Cash $14M$-78M$-18M$-5M$32M$-458M$398M$176M$-25M$-9M$-13M$-72M
Taxes Paid $1M$4M$2M$-2M$4M$-207.0K$-67.0K·····
Free Cash Flow ·····$-22M·$-95M$-33M$-72M$-85M·
Levered FCF ·····$-25M·$-104M$-45M$-93M$-104M·
Profitabilitas 8
Metrik Tren 202520242023202220212020201920182017201620152014
Gross Margin 56.6%35.6%53.9%··78.6%·76.2%75.2%73.6%65.9%62.2%
Operating Margin -23.5%-40.2%-22.0%··-3.2%·-47.2%-25.1%-50.4%-120.1%-177.0%
Net Margin -18.2%-35.9%-19.3%··-2.9%·-50.8%-37.5%-66.4%-140.9%-104.0%
Pretax Margin -16.9%-33.8%-17.5%··-2.8%·-50.8%-30.3%-58.7%-144.7%-109.2%
EBITDA Margin -23.5%-40.2%-22.0%··-3.2%·-47.2%-25.1%-50.4%-120.1%-177.0%
ROA -5.7%-10.8%-6.9%··-1.9%·-42.5%-41.3%-50.8%-66.9%-26.6%
ROE -8.4%-16.2%-10.7%··-2.9%·-234.1%183.0%124.9%105.9%92.2%
ROIC -11.8%-20.1%-13.5%··-3.3%·-46.6%-200.8%-80.6%417.0%-551.6%
Likuiditas & Solvabilitas 5
Metrik Tren 202520242023202220212020201920182017201620152014
Current Ratio 3.33.32.8··2.9·2.41.41.92.83.6
Quick Ratio 2.22.31.8··2.1·2.01.11.62.43.2
Debt / Equity ·····0.0·0.5-1.4-11.2-0.8-1.2
LT Debt / Equity ·······0.3-1.1-9.4-0.7-1.0
Interest Coverage -7167.1-13113.9-8448.5··-7.5·-12.2-4.7-3.5-4.9-5.2
Efisiensi 3
Metrik Tren 202520242023202220212020201920182017201620152014
Asset Turnover 0.30.30.4··0.7·0.81.10.80.50.3
Inventory Turnover ·····1.0·1.21.81.71.71.2
Receivables Turnover 1.71.82.3··4.5·4.15.57.77.59.4
Per Saham 5
Metrik Tren 202520242023202220212020201920182017201620152014
Book Value / Share $1.10$1.18$1.35··$1.60·$0.47$-0.24$-0.03$-0.70$-0.51
Revenue / Share $0.51$0.56$0.75··$1.61·$0.77$0.67$0.61$0.45$0.31
Cash Flow / Share $0.02$-0.08$0.02··$-0.06·$-0.32$-0.12$-0.34$-0.47$-0.42
Cash / Share $0.32$0.29$0.49··$0.48·$0.76$0.27$0.36$0.58$0.68
EPS (TTM) $-0.09$-0.20$-0.15$-0.26$0.02$-0.05$-0.07$-0.39$-0.25$-0.41$-0.83$-0.36
Tingkat Pertumbuhan 3
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue YoY -6.6%-25.5%-16.9%-36.7%-5.0%·······
Revenue CAGR 3Y -16.7%-26.8%-20.6%·········
Revenue CAGR 5Y -19.0%···········
Valuasi (TTM) 14
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue TTM $214M$229M$307M$369M$583M$614M$430M$229M$181M$130M$82M$54M
Net Income TTM $-39M$-82M$-59M$-106M$8M$-18M$-23M$-116M$-68M$-86M$-115M$-56M
Market Cap $5.81B$4.03B$7.11B··$38.39B·$88.70B$21.74B$16.59B$6.93B$3.42B
Enterprise Value ·····$37.89B·$88.53B$21.76B$16.60B$6.93B$3.41B
P/E -155.1-49.0-116.0-93.13370.0-1956.0-6125.7-697.9-320.8-150.2-45.5-54.4
P/S 27.217.623.2··62.5·387.0120.0127.684.863.1
P/B 12.78.312.9··61.2·582.3-333.9-1831.8-53.7-38.7
P / Tangible Book 13.08.613.417.141.562.6······
P / Cash Flow 863.6-130.01033.9··-1765.4·-936.6-661.9-231.0-81.8-47.3
P / FCF ·····-1745.2·-936.0-661.7-231.0-81.8·
EV / EBITDA ·····-1927.7·-818.0-477.6-252.9-70.6-35.5
EV / FCF ·····-1722.4·-934.2-662.3-231.0-81.8·
EV / Revenue ·····61.7·386.2120.1127.684.862.9
Earnings Yield -0.64%-2.0%-0.86%-1.1%0.03%-0.05%-0.02%-0.14%-0.31%-0.67%-2.2%-1.8%

Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·

Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir

16
Metrik 2025-12-312024-12-312023-12-312022-12-312021-12-31
Pendapatan $214M $229M $307M $369M $583M
Margin Kotor % 56.6% 35.6% 53.9% · ·
Margin Operasi % -23.5% -40.2% -22.0% · ·
Laba Bersih $-39M $-82M $-59M $-106M $8M
EPS Dilusian $-0.09 $-0.20 $-0.15 $-0.26 $0.02

Pemilik institusional (13F) 88 pengaju · $64.3M total · Per tanggal 30 Juni 2026

17

Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.

Pemegang 88
Nilai yang dipegang $64.3M
Posisi baru 21
Posisi yang keluar 7
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
Posisi baru Posisi yang keluar Meningkat Menurun Perubahan bersih saham
21 (+13 vs Kuartal sebelumnya) 7 (-12 vs Kuartal sebelumnya) 16 (-3 vs Kuartal sebelumnya) 14 (-1 vs Kuartal sebelumnya) +79K

Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.

Institusi Nilai Saham % dari 13F yang dilacak Tipe
Sarissa Capital Management LP $26.673.916 1.673.395 41,49% Saham
Kynam Capital Management, LP $8.495.733 532.982 13,22% Saham
MORGAN STANLEY $3.564.456 223.617 5,54% Saham
Waterfront Wealth Inc. $3.183.561 213.949 4,95% Saham
Brooklands Fund Management Ltd $2.741.449 177.325 4,26% Saham
Eversept Partners, LP $2.316.018 145.296 3,60% Saham
MILLENNIUM MANAGEMENT LLC $1.845.980 115.808 2,87% Saham
TWO SIGMA INVESTMENTS, LP $1.602.145 100.511 2,49% Saham
CITADEL ADVISORS LLC $1.520.103 95.364 2,36% Saham
BNP PARIBAS FINANCIAL MARKETS $1.144.699 71.813 1,78% Saham
LCM Capital Management Inc $818.710 51.362 1,27% Saham
RENAISSANCE TECHNOLOGIES LLC $771.002 48.369 1,20% Saham
SUSQUEHANNA INTERNATIONAL GROUP, LLP $765.120 48.000 1,19% Opsi beli
JANE STREET GROUP, LLC $599.790 37.628 0,93% Saham
George Kaiser Family Foundation $593.080 37.207 0,92% Saham
TWO SIGMA ADVISERS, LP $516.265 36.995 0,80% Saham
SEI INVESTMENTS CO $465.628 29.211 0,72% Saham
SUSQUEHANNA INTERNATIONAL GROUP, LLP $462.276 29.001 0,72% Saham
STATE STREET CORP $398.755 25.016 0,62% Saham
SUSQUEHANNA INTERNATIONAL GROUP, LLP $385.748 24.200 0,60% Opsi jual
Bleakley Financial Group, LLC $374.670 23.505 0,58% Saham
AMERIPRISE FINANCIAL INC $302.573 18.982 0,47% Saham
State of New Jersey Common Pension Fund D $300.931 18.879 0,47% Saham
CITADEL ADVISORS LLC $299.672 18.800 0,47% Opsi jual
COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS $292.818 18.370 0,46% Saham
RAYMOND JAMES FINANCIAL INC $289.550 18.165 0,45% Saham
R Squared Ltd $269.992 16.938 0,42% Saham
State of Tennessee, Department of Treasury $239.164 15.004 0,37% Saham
Quadrature Capital Ltd $236.581 14.842 0,37% Saham
Quinn Opportunity Partners LLC $228.022 14.305 0,35% Saham
Cubist Systematic Strategies, LLC $224.390 13.699 0,35% Saham
WELLS FARGO & COMPANY/MN $221.773 13.913 0,34% Saham
EntryPoint Capital, LLC $194.882 12.226 0,30% Saham
Jump Financial, LLC $191.407 12.008 0,30% Saham
GEODE CAPITAL MANAGEMENT, LLC $187.629 11.771 0,29% Saham
OSAIC HOLDINGS, INC. $184.333 11.565 0,29% Saham
NJ State Employees Deferred Compensation Plan $178.542 10.900 0,28% Saham
Verdad Advisers, LP $166.270 10.431 0,26% Saham
CITADEL ADVISORS LLC $164.182 10.300 0,26% Opsi beli
UBS Group AG $160.404 10.063 0,25% Saham
Steward Partners Investment Advisory, LLC $142.025 8.910 0,22% Saham
NEW YORK STATE COMMON RETIREMENT FUND $121.224 7.605 0,19% Saham
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO $92.038 5.774 0,14% Saham
Federation des caisses Desjardins du Quebec $73.518 4.615 0,11% Saham
RHUMBLINE ADVISERS $59.498 3.733 0,09% Saham
NATIONAL BANK OF CANADA /FI/ $40.137 2.518 0,06% Saham
ROYAL BANK OF CANADA $30.000 1.877 0,05% Saham
GAMMA Investing LLC $25.121 1.576 0,04% Saham
NewEdge Advisors, LLC $21.471 1.347 0,03% Saham
Farther Finance Advisors, LLC $15.271 958 0,02% Saham

Tampilkan semua 88 pemilik institusional →

Aktivis & pemilik 5%+ 35 saham

18

Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.

Pengaju Diajukan Kepemilikan Status Tujuan Pengajuan
Alexander J Denner, Sarissa Capital Management LP 27 Agu 2026 6,09% Amandemen · SEC
Sarissa Capital Management LP, Alexander J Denner ×3 pengajuan 25 Maret 2025 8,08% Amandemen Kampanye dewan SEC
28 Feb. 2023 · Pengajuan awal · SEC
27 Feb. 2023 · Pengajuan awal · SEC
21 Feb. 2023 · Pengajuan awal · SEC
OR ×6 pengajuan 15 Feb. 2023 · Pengajuan awal · SEC
14 Feb. 2023 · Pengajuan awal · SEC
10 Feb. 2023 · Pengajuan awal · SEC
19 Jan. 2023 · Pengajuan awal · SEC
16 Juni 2022 · Pengajuan awal · SEC
Sofinnova Venture Partners VII, L.P. (“SVP VII”), Sofinnova Management VII, L.L.C. (“SM VII”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Eric P. Buatois (“Buatois”) ×4 pengajuan 23 Agu 2013 · Pengajuan awal Investasi pasif SEC
Abingworth LLP 98-051-8585, Abingworth Bioventures V Co-Invest Growth Equity Fund LP 98-057-9772, Abingworth Bioventures V L.P. 98-051-8587, Abingworth Bioequities Master Fund Limited 66-066-0960 ×10 pengajuan 22 Juli 2013 · Pengajuan awal Kampanye dewan SEC
Boxer Capital, LLC, Boxer Asset Management Inc., Joseph Lewis ×4 pengajuan 24 Agu 2011 · Pengajuan awal · SEC
OrbiMed Advisors LLC, OrbiMed Capital GP III LLC, Samuel D. Isaly ×14 pengajuan 28 April 2011 · Pengajuan awal · SEC
Fountain Healthcare Partners Fund 1, L.P. (“ Fountain ”), Fountain Healthcare Partners Ltd., Manus Rogan, Aidan King, Ena Prosser, Justin Lynch ×2 pengajuan 10 Des. 2010 · Pengajuan awal · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Orang dalam perusahaan 43 orang dalam · 18 pejabat · 27 direktur

19
Orang Dalam Peran Aktivitas terakhir Saham dimiliki Beli 12m Jual 12m Bersih 12m
Aaron Berg President and CEO 26 Juni 2026 M 85.648 0 0 $0
Patrick Holt President and CEO 22 Jan. 2024 P 314.426 0 0 $0
Karim Mikhail President and CEO 21 Feb. 2023 A 283.507 0 0 $0
John F Thero President and CEO 30 Juli 2021 M 3.252.752 0 0 $0
Peter L. Fishman SVP, CFO 1 Agu 2026 A 7.619 0 0 $0
Thomas Charles Reilly EVP and CFO 1 Juli 2024 M 94.305 0 0 $0
Michael Wayne Kalb SVP and CFO 29 Juli 2022 M 337.314 0 0 $0
David Paul Keenan EVP, Chief Operating Officer 1 Juli 2026 A 13.470 0 0 $0
Jonathan Provoost EVP, Chief Legal Officer 1 Juli 2026 A 4.624 0 0 $0
Steven B Ketchum EVP, Chief Scientific Officer 1 Juli 2026 A 42.680 0 0 $0
Jason M. Marks EVP,Chief Global Legal Officer 19 Agu 2022 M 21.917 0 0 $0
Joseph T Kennedy General Counsel 30 Juli 2021 M 317.860 0 0 $0
Mark Salyer Chief Commercial Officer 1 Feb. 2018 A · 0 0 $0
Michael James Farrell VP, Finance 1 Feb. 2016 A 30.190 0 0 $0
Paul Huff Chief Commercial Officer 26 Juli 2012 A 0 0 0 $0
Stuart D Sedlack Senior Vice President 26 Juli 2012 A 0 0 0 $0
Paresh Soni SVP and Head of Development 1 Feb. 2012 A 0 0 0 $0
Frederick W Ahlholm Vice President Finance 1 Feb. 2012 A 0 0 0 $0
Oliver O'Connor Direktur 18 April 2026 M 801 0 0 $0
Paul Cohen Direktur 18 April 2026 M 836 0 0 $0
Diane E. Sullivan Direktur 18 April 2026 M 836 0 0 $0
Louis Sterling III Direktur 18 April 2026 M 4.049 0 0 $0
Patrice Eadon Bonfiglio Direktur 18 April 2026 M 836 0 0 $0
Keith Horn Direktur 18 April 2026 M 836 0 0 $0
Odysseas D Kostas Direktur 18 April 2026 M 836 0 0 $0
Mark Dipaolo Direktur 18 April 2025 M 401 0 0 $0
Olsen Per Wold Direktur 10 Jan. 2023 M 171.027 0 0 $0
Murray Stewart Direktur 9 Jan. 2023 A · 0 0 $0
Adam Mark Berger Direktur 20 Okt. 2022 A · 0 0 $0
Geraldine Murphy Direktur 20 Okt. 2022 A · 0 0 $0
Alfonso G Zulueta Direktur 27 Juni 2022 A · 0 0 $0
Erin S. Enright Direktur 27 Juni 2022 A · 0 0 $0
Kristine Peterson Direktur 27 Juni 2022 A 0 0 0 $0
Patrick J O'Sullivan Direktur 27 Juni 2022 A · 0 0 $0
Lars Ekman Direktur 27 Juni 2022 A 0 0 0 $0
VAN HEEK G JAN Direktur 27 Juni 2022 A 14.168 0 0 $0
Joseph S Zakrzewski Direktur 15 Des. 2021 P 196.547 0 0 $0
David M Stack Direktur 14 Juni 2021 A 40.000 0 0 $0
Dr. James I. Healy Direktur 11 Juli 2016 A 90.000 0 0 $0
GORDON CARL L Direktur 4 Sep. 2012 S 5.700 0 0 $0
Joseph Anderson Direktur 10 Juli 2012 A 11.683 0 0 $0
David W Feigal Jr Direktur 12 Juli 2011 A · 0 0 $0
Abingworth LLP Pemilik 10% 19 April 2012 S 1.599.168 0 0 $0

Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka

AMRN Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan

21
peringkat · 7 analis JUAL
Target median $12.50 +1,2%
0 0,0% Beli Kuat
0 0,0% Beli
2 28,6% Tahan
3 42,9% Jual
2 28,6% Jual Kuat

Target Harga 12 Bulan

2 analis · 2026-10-03

Target rata-rata $12.50 +1,2%

Sekarang Harga saat ini $12.35
Rendah$12.00 Rata-rata$12.50 Tinggi$13.00

Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor

22

Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.

Ticker Kapitalisasi Pasar P/E Pendapatan YoY Margin Bersih ROE Margin Kotor
AMRN $5.81B -155.1 -6.6% -18.2% -8.4% 56.6%
ALKS $4.63B 19.6 -5.2% 16.4% 14.0% ·
PRTA $514M -2.1 -92.8% -2520.6% -63.6% ·

Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap

26

Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.

Pilihan Anda disimpan dan mengikuti Anda di semua ticker.

Sumber: SEC 10-Q diajukan Jul 29, 2026